BACKGROUND: In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated withexemestane, anastrozole, or tamoxifenfor postoperative adjuvant therapy. PATIENTS AND METHODS: A total of 154 breast cancer patients were assigned to receive exemestane, anastrozole, or tamoxifen in this randomized open-label study. Serum lipid parameters including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured during 1 year of treatment. RESULTS:TC and LDL-C rapidly decreased in patients treated with tamoxifen at 3 months. Compared with anastrozole and exemestane patients, TC and LDL-C were significantly lower at all assessment time points in tamoxifenpatients (P < 0.05). TG increased in tamoxifen patients; it was significantly higher compared with exemestane patients at all assessment time points (P < 0.05). HDL-C slightly decreased in exemestane patients; it was significantly lower compared with anastrozole patients at 3 months and 1 year (P = 0.0179 and 0.0013, respectively). CONCLUSION: Changes of lipid profiles in Japanese postmenopausal women treated withtamoxifen were relatively favorable, while exemestane and anastrozole had no clinically significant effect on the serum lipids.
RCT Entities:
BACKGROUND: In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy. PATIENTS AND METHODS: A total of 154 breast cancerpatients were assigned to receive exemestane, anastrozole, or tamoxifen in this randomized open-label study. Serum lipid parameters including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured during 1 year of treatment. RESULTS:TC and LDL-C rapidly decreased in patients treated with tamoxifen at 3 months. Compared with anastrozole and exemestanepatients, TC and LDL-C were significantly lower at all assessment time points in tamoxifenpatients (P < 0.05). TG increased in tamoxifenpatients; it was significantly higher compared with exemestanepatients at all assessment time points (P < 0.05). HDL-C slightly decreased in exemestanepatients; it was significantly lower compared with anastrozolepatients at 3 months and 1 year (P = 0.0179 and 0.0013, respectively). CONCLUSION: Changes of lipid profiles in Japanese postmenopausal women treated with tamoxifen were relatively favorable, while exemestane and anastrozole had no clinically significant effect on the serum lipids.
Authors: Charles E Wood; Stephen M Boue; Bridgette M Collins-Burow; Lyndsay V Rhodes; Thomas C Register; J Mark Cline; Fitriya N Dewi; Matthew E Burow Journal: J Agric Food Chem Date: 2011-12-19 Impact factor: 5.279
Authors: Judy N Jacobse; Lars C Steggink; Michael Schaapveld; Gabe S Sonke; Annemiek van Ommen-Nijhof; Joop D Lefrandt; Jourik A Gietema; Flora E van Leeuwen Journal: Breast Cancer Res Treat Date: 2022-10-01 Impact factor: 4.624
Authors: Anna J Lomax; Saw Yee Yap; Karen White; Jane Beith; Ehtesham Abdi; Adam Broad; Sanjeev Sewak; Chooi Lee; Philip Sambrook; Nicholas Pocock; Margaret J Henry; Elaine G Yeow; Richard Bell Journal: J Bone Oncol Date: 2013-08-15 Impact factor: 4.072